COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01281124
Recruitment Status : Completed
First Posted : January 21, 2011
Results First Posted : September 13, 2013
Last Update Posted : September 24, 2019
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Condition or disease Intervention/treatment Phase
Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Non-Small Cell Cancer AJCC v7 Drug: Azacitidine Other: Diagnostic Laboratory Biomarker Analysis Other: Pharmacological Study Phase 2

Detailed Description:


I. To determine the ability of 5-azacytidine to cause DNA hypomethylation and re-expression of silenced tumor suppressor genes when stratified for high or low expression of mir29a, b, and c.


I. To compare the molecular studies (mir29 expression and tumor suppressor gene methylation) between archival tissue, fresh biopsy pre-treatment samples, and post-treatment fresh samples.

II. To determine the overall response rate by CT (RECIST 1.1 criteria) and PET (EORTC PET response criteria), PFS, and OS of patients treated with azacytidine in the second- or third-line setting.

III. To correlate the blood microRNA profiles (and changes in microRNA profiles) with response to azacytidine.


Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo tissue and blood sample collection at baseline and periodically during study treatment for correlative studies. After completion of study treatment, patients are followed up for 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC
Actual Study Start Date : January 12, 2011
Actual Primary Completion Date : April 15, 2011
Actual Study Completion Date : September 12, 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Azacitidine

Arm Intervention/treatment
Experimental: Treatment (azacitidine)
Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Azacitidine
Given subcutaneously
Other Names:
  • 5 AZC
  • 5-AC
  • 5-Azacytidine
  • 5-AZC
  • Azacytidine
  • Azacytidine, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza

Other: Diagnostic Laboratory Biomarker Analysis
Correlative studies

Other: Pharmacological Study
Correlative studies

Primary Outcome Measures :
  1. DNA Hypomethylation and Re-expression of Silenced Tumor Suppressor Genes When Stratified for Low or High Expression of mir29 [ Time Frame: Up to 12 weeks after completion of study treatment ]
    The change in mean methylation of the genes between the patients with a low mir29 and a high mir29 expression will be evaluated by a two-sample t-test. Secondary analyses include a multivariate regression where all 5 changes in methylation will be regressed on mir29 expression (low vs. high) and adjusted for patient demographic and clinical attributes at baseline.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: From the day of initial treatment until death (from any cause), assessed up to 12 weeks after completion of study treatment ]
    Analyzed using a Kaplan-Meier methods.

  2. Progression-free Survival [ Time Frame: From the day of initial treatment until documented disease progression (per PET) or death, assessed up to 12 weeks after completion of study treatment ]
    Analyzed using a Kaplan-Meier methods.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced (stage 4 or recurrent) NSCLC, not eligible for any curative intent treatment

    • Tumor must be histologically or cytologically confirmed
  • Measurable disease (as defined by RECIST criteria)
  • Patients may have up to two (and at least one) prior cytotoxic regimens in the metastatic setting

    • Prior adjuvant chemotherapy following resection or definitive chemo-radiation for patients with locally advanced disease is not included in this
    • Allowable systemic therapy in the metastatic setting includes 2 cytotoxic regimens and erlotinib and/or other non-cytotoxic drugs (i.e., erlotinib, sorafenib, and other tyrosine kinase inhibitors do not count as a "cytotoxic regimen")
    • Prior adjuvant therapy or definitive chemo-radiation is allowed if completed > six months before the onset of "first-line" therapy in the metastatic setting - in this setting, adjuvant or definitive chemo-radiation will not "count" as one of the two cytotoxic regimens; if however, the patient relapses within six months from completion of adjuvant or definitive chemoradiation, then this therapy will be considered the first-line cytotoxic therapy
    • In the unusual circumstance where patients receive "adjuvant" therapy following resection of oligo-metastatic disease (for example brain metastasis and lung primary resections) and the treating physician decides to administer chemotherapy following all surgery, this will be considered "adjuvant" therapy and the same rules as noted above will apply for initiation of first-line systemic therapy
  • No patients with uncontrolled brain metastases or leptomeningeal disease

    • Patients with controlled brain metastases are allowed
  • ECOG performance status 0-2
  • Absolute neutrophil count ≥ 1.5 x 10^9/L
  • Platelets ≥ 100,000 x 10^9/L
  • Hemoglobin ≥ 9.0 gm/100 mL
  • Total bilirubin ≤ 1.5 mg/dL
  • AST and ALT ≤ 2.5 x ULN
  • Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance > 50 mL/min
  • No patients who are pregnant
  • Women of childbearing potential must have a negative pregnancy test
  • The patient must be willing to use adequate contraception for the duration of study treatment and up to four weeks following the last dose of drug
  • Archival diagnostic material sufficient for microRNA evaluation/assessment is preferred, though optional

    • The presence of archival material will not preclude the need for pre and post treatment biopsies
  • Willing to undergo biopsy pre-treatment and following first cycle

    • Biopsy may be from any accessible site (primary or metastatic)
  • No known HIV or hepatitis B or C (though testing for this is not required)
  • No uncontrolled intercurrent illness including, but not limited to:

    • Symptomatic CHF
    • Unstable angina pectoris
    • Serious cardiac arrhythmia
    • Serious infection
    • Psychiatric illness or social situations that would limit compliance with study requirements
  • No patients who have significant psychiatric illness that, in the opinion of the principal investigator, would prevent adequate informed consent or render therapy unsafe
  • Patients may not have had a prior invasive malignancy except for adequately treated non-melanoma cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 2 years

    • For example, a stage 1 (T1c) prostate cancer 2 years prior to a diagnosis of NSCLC would not be exclusionary, however, a metastatic prostate cancer currently receiving hormonal or chemotherapy would be excluded
  • No other concurrent palliative radiotherapy
  • Recovered from prior surgery, radiation, or chemotherapy to ≤ grade 2 toxicity
  • Palliative radiation or surgical procedures (for example, endobronchial therapy) is allowed, but must have been completed > 2 weeks prior to starting treatment
  • No other investigational or commercial agents or therapies may be administered with the intent to treat the patient's malignancy
  • No other concurrent investigational therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01281124

Layout table for location information
United States, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Gregory A Otterson Ohio State University Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT01281124    
Other Study ID Numbers: NCI-2011-02570
NCI-2011-02570 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
OSU 10100 ( Other Identifier: Ohio State University Comprehensive Cancer Center )
8617 ( Other Identifier: CTEP )
N01CM00070 ( U.S. NIH Grant/Contract )
P30CA016058 ( U.S. NIH Grant/Contract )
First Posted: January 21, 2011    Key Record Dates
Results First Posted: September 13, 2013
Last Update Posted: September 24, 2019
Last Verified: September 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors